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Abstract
Characterisation of long-term adherence to EPA and DHA intakes through biomarkers and dietary assessments has implications for
interpreting the findings of long-term intervention studies. Adherence to dietary advice targeting an EPA þ DHA intake of 1 g/d was exam-
ined over 1 year. Men and women (n 45) received dietary advice to increase EPA and DHA intakes from seafood, nutraceutical (fish oil)
or functional food sources, while a fourth group received combined advice. Blood biomarkers and dietary intakes of EPA and DHA were
evaluated at baseline and post-intervention at weeks 4, 8, 12, 24 and 52. Assessment by 3 d diet records indicated that EPA þ DHA intakes
increased relative to baseline in weeks 4–52 following the seafood, nutraceutical and combined advice (advice group £ time effect,
P¼0·03). The percentage of DHA in plasma and whole blood and the percentage of EPA in erythrocytes, plasma and whole blood
were higher in weeks 4–52 when compared with the corresponding baseline measurement. In contrast, the percentage of DHA in eryth-
rocytes increased to a maximum at week 12 and returned to baseline levels in weeks 24 and 52 (time effect, P,0·01). Measurement of
the percentage of DHA in erythrocytes indicates that adherence was sustained during the first 12 weeks following the dietary advice,
while other blood measurements of the percentage of EPA and DHA and dietary assessment suggest short-term increases in
EPA þ DHA intakes immediately before weeks 24 and 52. The percentage of DHA in erythrocytes characterises adherence to EPA and
DHA intakes in long-term interventions.
Key words: EPA: DHA: Adherence: Biomarkers: Functional foods: Nutraceuticals
The n-3 highly unsaturated fatty acids (HUFA; $20 carbons,
$3 double bonds) EPA and DHA exert cardio-protective
effects through several physiological and molecular mechan-
isms(1,2). Current EPA þ DHA intake recommendations range
from 0·25 to 4 g/d with guidelines ,1 g/d aimed at healthy
individuals and those $1 g/d advised for secondary CVD
prevention and TAG lowering(3–7). In contrast, median North
American intakes of EPA and DHA of 0·11 g/d by women
and 0·16 g/d by men fall below existing guidelines(8).
Recent trials(9–11) and meta-analyses(12,13) have found no
reduction in CHD risk with EPA and DHA intakes. However,
the intention-to-treat approach used in these trials may fail
to account for a lack of long-term adherence with study diet-
ary protocols. Adherence up to but not beyond 3 months has
been observed by diet history interviews following the advice
to increase EPA and DHA intakes from oily fish(14). Blood fatty
acid composition offers an objective strategy to measure
intake, as this tissue is responsive to dietary EPA and
DHA(15–17). In blood, there are numerous blood fractions
(plasma, erythrocytes, platelets and leucocytes) and lipid
classes (phospholipids, TAG and cholesteryl esters) that can
be analysed. Plasma and erythrocytes tend to be routinely
collected in clinical studies, with fingertip blood sampling
methods resulting in increasing reports of whole-blood fatty
acids. While it is possible to isolate specific lipid classes
before fatty acid analyses, the examination of total lipid fatty
acids greatly enables cost-efficient, high-throughput analyses
required for clinical screening and monitoring(18). Erythrocyte
fatty acid composition is often cited as a preferred blood
marker of long-term intakes as the cell lifespan is 120 d(19),
although some exchange with plasma fatty acids(20) and mem-
brane bilayer remodelling is possible(21,22). When compared
with erythrocytes, plasma responds more rapidly to increases
and decreases in EPA þ DHA intakes(17,20). Whole blood will
respond to changes in EPA þ DHA intakes in a manner inter-
mediate between plasma and erythrocytes(17). Furthermore,
when compared with DHA, levels of EPA in whole blood
will increase and decrease more rapidly in response to the
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start and termination of fish oil supplementation(17). Charac-
terising the ability of different blood fatty acid biomarkers
to capture long-term adherence to EPA and DHA intakes
could assist in the design and interpretation of long-term trials.
Dietary advice to increase EPA and DHA intakes can vary.
The majority of clinical intervention studies use a nutraceutical
approach by supplementing with fish oil. Conventional
dietetic practice advises a whole-food approach based on
fish intake to reach the level recommended for EPA and
DHA intake guidelines(6,7). Novel functional foods may pro-
vide additional options to cost-effectively increase EPA and
DHA intakes(23). Fish(24), nutraceutical(9,11,25) and functional
food(10) sources have been used to examine the relationship
between EPA and DHA intakes and CHD risk. Long-term
adherence by men and women to dietary advice based on sea-
food, functional foods and nutraceuticals in a self-selected
manner has not been evaluated through comprehensive
blood fatty acid analyses.
The purpose of the present study was to examine, through
dietary assessment and blood biomarkers, adherence over
1 year to dietary advice to increase EPA and DHA intakes.
Adherence to dietary advice strategies based on seafood,
nutraceuticals and/or functional foods was examined.
Subjects and methods
Study population
Participants aged 35–50 years were sought from the
Kitchener–Waterloo, Ontario area using local newspaper
advertisements and flyers posted at local community centres,
grocery stores and on the University of Waterloo campus.
At a screening visit, individuals provided a fasting fingertip
prick blood sample, completed a semi-quantitative FFQ
specific for EPA and DHA intakes(26) and were given instruc-
tions for completing a 3 d diet record. Individuals with .4 %
EPA þ DHA levels in total fatty acids from fingertip prick
blood samples, existing CVD or diabetes mellitus and those
consuming nutraceuticals containing EPA and DHA were
excluded from the study. The present study was conducted
according to the guidelines laid down in the Declaration of
Helsinki, and all procedures involving human participants
were approved by the University of Waterloo Human Ethics
Committee. Written informed consent was obtained from
all participants.
Study design
Participants attended a baseline visit approximately 2 weeks
after screening where dietary advice was provided as a struc-
tured interview and handout. Participants were asked to
follow the advice for the subsequent 52 weeks. A fasting
venous blood sample, a 3 d diet record and anthropometric
measurements were collected at baseline and at follow-up
visits in weeks 4, 8, 12, 24 and 52. Participants were instructed
to collect duplicates of all foods, beverages and nutraceuticals
consumed on the 3 d corresponding with the 3 d diet record
returned at the week 4 visit.
Dietary advice
Participants were stratified by sex and allocated in the order
in which they were admitted to the trial to one of the four diet-
ary advice groups consisting of seafood, functional food,
nutraceutical or combined advice. Participants were not
provided food products or nutraceuticals as the study was
designed to examine the response to dietary advice. The
study was not blinded due to the nature of the intervention.
At the baseline visit, participants received the same infor-
mation regarding the health benefits associated with EPA
and DHA intakes and were advised to target the dietary
intake of 1 g EPA þ DHA/d. The Seafood advice group was
asked to substitute seafood in place of other meat and meat
alternatives in their regular diets. Information on local seafood
retailers, safe seafood preparation and cooking techniques,
recipes, sample daily menus and recommendations for avoid-
ing frequent intake of fish with high mercury content was
provided. Differences in the EPA þ DHA content of oily and
lean fish were discussed and the amount of EPA þ DHA of
all seafood itemised in the Canadian Nutrient File 2007b(27)
was provided to help participants estimate the EPA þ DHA
intake. The Functional Food advice group was asked to substi-
tute EPA- and/or DHA-containing functional foods in place of
similar foods in their regular diets (e.g. n-3 eggs in place of
regular eggs). Information on how to identify functional
foods containing EPA and/or DHA from product labels,
recipes, sample daily menus and the amount of EPA þ DHA
per serving of available functional foods along with cost com-
parisons at local retail outlets was provided to the Functional
Food advice group. The Nutraceutical advice group was
advised to supplement their regular diet with a nutraceutical
product. Information on the different types of nutraceutical
products available (e.g. capsules, liquid, soft chews, etc.),
the interpretation of product labels and the cost associated
with consuming 1 g EPA þ DHA/d from various nutraceutical
products from local retail outlets was provided. The Combined
advice group was given the seafood, functional food and
nutraceutical advice and advised on how to simultaneously
substitute/supplement their diet with all the three sources
by providing sample daily menus.
Outside of recommendations to increase EPA þ DHA
intakes through substitution/supplementation, all groups
were otherwise requested to maintain their usual diets. Partici-
pants were responsible for purchasing their own food and/or
nutraceutical products, but remuneration for participation
in the study was designed to compensate for these expenses.
At follow-up visits in weeks 4–52, the 3 d diet records detailing
the intakeof recommended foods/nutraceuticalswere reviewed
in-person, challenges associated with following the dietary
advice were discussed and continued adherence was encour-
aged. The baseline (dietary advice) visit took up to 1 h and
visits in weeks 4–52 took up to 30 min, including blood
sample and anthropometric measurement collection. Research-
ers were available to answer questions from the participants
between the study visits by phone or email. The assumption
was made that seafood, functional foods and nutraceuticals
supply EPA and DHA in an equally bioavailable manner(28–31).
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Blood sampling
All blood sampling was performed following an 8–12 h
overnight fast. Screening fingertip prick blood samples were
collected by puncturing the skin with a disposable lancing
device (Capiject; Terumo or Unistik 2; Lifescan) and absorbing
blood onto a 1 cm2 area of chromatography paper (Whatman)
pre-washed in 4:1 chloroform–methanol(32,33). Venous blood
samples were collected by venepuncture into evacuated
tubes (Vacutainer; Becton Dickinson). The anti-coagulant
EDTA (Sigma-Aldrich) was added to venous blood samples
in preparation for fatty acid determination of whole blood,
plasma and erythrocyte aliquots. Erythrocytes were washed
twice with saline before collection. All venous blood samples
were stored at 2808C until analysis.
Dietary assessment and food duplicate collections
The 3 d diet records included two weekdays and one
weekend day. Completed dietary surveys, including the
screening FFQ and 3 d diet records, were checked by a
single researcher for clarification and completeness. Dietary
surveys were analysed using the Food Processor SQL Edition
dietary analysis software (version 10.6.0; ESHA Research).
The software food composition database was also updated
with the Canadian Nutrient File 2007b database(27) and fatty
acid compositions of select functional food and nutraceutical
products directly assayed by GC in the laboratory. Food
duplicate collections were weighed, blended to homogeneity
in a 4-litre blender (Waring Laboratory & Science) and stored
at 2808C until fatty acid analysis.
Fatty acid composition analyses
The fatty acid compositions of venous blood fractions,
fingertip prick blood samples, food duplicate collections,
and nutraceuticals and functional foods identified on dietary
surveys were assessed. All lipids were extracted in the pre-
sence of butylated hydroxytoluene (Sigma-Aldrich) to prevent
lipid oxidation. An internal standard (22 : 3n-3 ethyl ester;
Nu-Check Prep) was added during venous blood and food
duplicate analyses to allow for quantitative determinations.
Qualitative fatty acid determinations for screening pur-
poses were rapidly determined from fingertip prick blood
samples(32,33). Briefly, fingertip prick samples were directly
transesterified without prior lipid extraction by placing
chromatography paper saturated with blood in 14 % boron
trifluoride in methanol (Thermo Scientific) with hexane on a
908C heat block for 1 h. Venous whole blood and plasma
lipids were extracted using a Folch-based method(34), while
erythrocyte lipids were extracted by a Bligh and Dyer-based
method(35) with steps to ensure erythrocyte cell membrane
lysis(36). Fatty acid methyl esters were then prepared from
the isolated lipid extracts by transesterification with 14 %
boron trifluoride in methanol (Thermo Scientific) with
hexane on a 908C heat block for 1 h(37). Oils isolated from
nutraceuticals were prepared by lipid extraction and sub-
sequent transesterification as described above for whole
blood and plasma. The fatty acid composition of nutraceutical
and functional food products, and food duplicate collections
were determined in triplicate. Briefly, AOAC International
method 996.06, with solvent volume adjustment for samples
containing 6·25–12·5 mg of total fat(38), was modified
with initial acid hydrolysis treatment for complete lipid
extraction from microencapsulated fish oil(39) and fatty acid
methyl esters prepared as described above. The fatty acid
methyl esters in hexane were collected and analysed on a
Varian 3900 gas chromatograph (Varian) with settings as
described previously(40). Both identified(32) and unidentified
peaks were included in the total fatty acid summation when
individual fatty acids were expressed as a percentage of the
total fatty acid pool.
Statistical and data analyses
Blood EPA and DHA measurements expressed as individual
fatty acids and composite fatty acid biomarkers, in addition
to dietary intake of EPA þ DHA from 3 d diet records, were
evaluated as the primary study outcomes. Blood measure-
ments of n-3 docosapentaenoic acid (DPAn-3, 22 : 5n-3)
were also examined, as this fatty acid may exert cardio-
protective effects(2). Individual fatty acids were expressed
as a percentage of total fatty acids (blood) or as mass per d
(dietary intake). The sum of the percentage of EPA þ DHA
and EPA þ DPAn-3 þ DHA and the percentage of n-3 HUFA
in total HUFA were also examined, as they are the proposed
biomarkers of n-3 status(41–44). The percentage of n-3 HUFA
in total HUFA was calculated using the following formula:
(20 : 5n-3 þ 22 : 5n-3 þ 22 : 6n-3)/(20 : 5n-3 þ 22 : 5n-3 þ 22 :
6n-3 þ 20 : 3n-6 þ 20 : 4n-6 þ 22 : 4n-6 þ 22 : 5n-6) £ 100(18).
Measurements of HUFA intakes from 3 d diet records were
loge transformed to permit parametric statistical analyses.
All statistical analyses were performed using SPSS
(release 18.0.0; IBM). Significance was set at P,0·05 and sig-
nificance levels quoted are two-sided. The linear mixed
model procedure was used for ANOVA. Following the determi-
nation of a significant F-value, individual means were exam-
ined with Bonferroni’s post hoc analyses. All blood and diet
record measurements of EPA and DHA were evaluated using
a three-factor (advice group, sex and time) repeated-measures
linear mixed model procedure. Measurements of EPA and
DHA intakes by 3 d diet records and 3 d food duplicate collec-
tions in week 4 were compared by paired t tests.
Results
Participant flow and characteristics
Study recruitment was initiated in January 2008 and contin-
ued for 8 months. A total of fifty-nine individuals responded
to advertisements and were screened for study participation
(see CONSORT flow diagram in the supplementary material).
Of these individuals, nine did not meet eligibility require-
ments and were not admitted. Following the baseline dietary
advice intervention, five individuals initially recruited left
the study: one was diagnosed with gallstones; one became
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pregnant; one was attempting to become pregnant; one was
unable to attend the study visits; one could not be contacted.
As blood fatty acid composition would change with gall-
stonec treatment and pregnancy, these two participants
were excluded from all analyses. The remaining three indi-
viduals not completing the study had been allocated to the
Seafood advice group (one female and one male) and the
Functional Food advice group (one female). Intention-to-
treat analysis using the baseline values from the three drop-
outs for all time points did not alter the findings presented
herein. As a result, measurements from the forty-five individ-
uals who participated in the year-long study are reported. Of
these forty-five individuals, eleven (six females and five
males) were assigned to each of the Seafood, Functional
Food and Combined advice groups and twelve (six females
and six males) were assigned to the Nutraceutical advice
group. Participants were mainly Caucasian, educated
beyond high school and not regular smokers. The dietary
advice groups were similar in BMI (baseline 27·3 (SD
5·3) kg/m2) and age (baseline 43·7 (SD 4·4) years). No adverse
events were reported following the dietary advice.
Dietary intake of EPA þ DHA
By the 3 d diet records, intake of EPA þ DHA was found to
be 0·12 (95 % CI 0·07, 0·21) g/d at baseline. In the Seafood,
Nutraceutical and Combined advice groups, EPA þ DHA
intake increased at each post-intervention time point from
each advice group’s own baseline measurement (effect of
the advice group £ time interaction, P¼0·03; Fig. 1). In the
Functional Food group, EPA þ DHA intake did not increase
significantly post-intervention. At each time point, no significant
differences in EPA þ DHA intake were detected between the
advice groups. In the Seafood advice group, the measurement
of EPA intake in week 4 was lower when assessed by food dupli-
cates when compared with diet records (P¼0·04; Table 1).
Otherwise, EPA and/or DHA estimates were similar when
assessed by the 3 d diet record and food duplicate collection.
Blood fatty acids and fatty acid biomarkers
A three-way interaction was observed for the percentage of
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Fig. 1. Intake of the sum of EPA and DHA from 3 d diet records in (a) the Seafood, (b) Nutraceutical, (c) Functional Food and (d) Combined advice groups by
completers. Values are back-transformed loge means (geometric means, n 45), with standard deviations represented by vertical bars. * Mean value was signifi-
cantly different from that of the week 0 measurement (P,0·05; Bonferroni’s post hoc test following a significant F-value by the repeated-measures linear mixed
model procedure).
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meaningful comparisons shown). This biomarker was 2·87
(SD 0·95) % at baseline. In the Seafood advice group, the percen-
tage of EPA þ DHA in the whole blood biomarker increased
from baseline in weeks 4, 12, 24 and 52 for men and in weeks
4 and 12 for women. For men and women in the Functional
Food advice group, the biomarker did not increase significantly
from baseline. In the Nutraceutical advice group, the biomarker
increased from baseline in weeks 12 and 52 for men and in
weeks 4–52 for women. The biomarker increased from baseline
in weeks 24 and 52 for men in the Combined advice group.
For women in the Combined advice group, the biomarker
increased at all time points after baseline. A three-way inter-
action was similarly observed for the percentage of EPA þ
DPAn-3 þ DHA in whole blood (P¼0·01) and the percentage
of n-3 HUFA in the total HUFA biomarker in whole blood
(P,0·01).
Overall, the percentage of DHA in erythrocytes increased
from baseline (4·0 (SD 1·0) %) in weeks 4 and 8, reached a
maximum in week 12 (4·9 (SD 0·8) %) and subsequently
returned to baseline levels in weeks 24 and 52 (effect of
time, P,0·01) (Fig. 3). The percentage of DHA in erythrocytes
was higher overall in the Seafood advice group (4·7 (SD 1·0) %)
when compared with the Functional Food (4·0 (SD 0·8) %)
and Nutraceutical (4·0 (SD 0·9) %) advice groups (effect of
advice group, P,0·01). In contrast to the percentage of
DHA in erythrocytes, the percentage of DHA in plasma and
whole blood, the percentage of EPA in all the three blood frac-
tions and the percentage of DPAn-3 in plasma and whole
blood were higher in weeks 4–52 when compared with
the corresponding baseline measurement (Fig. 3). In erythro-
cytes, the percentage of DPAn-3 was higher in weeks 12–52
when compared with the week 0 measurement. The percen-
tage of the EPA þ DHA biomarker in erythrocytes increased
relative to the baseline measurement in weeks 4–24, and
returned to baseline levels in week 52. The percentage of
Table 1. EPA and DHA estimates by 3 d diet records and 3 d food
duplicate collections in week 4
(Geometric means (loge transformed) and 95 % confidence intervals)
3 d diet records (g/d)
3 d food duplicates
(g/d)
Mean 95 % CI Mean 95 % CI
EPA
All (n 45) 0·37 0·27, 0·51 0·30 0·21, 0·41
Seafood 0·48 0·30, 0·75 0·31* 0·22, 0·44
Functional Food 0·15 0·05, 0·48 0·12 0·05, 0·29
Nutraceutical 0·60 0·51, 0·71 0·62 0·32, 1·19
Combined 0·40 0·29, 0·55 0·32 0·20, 0·53
DHA
All (n 45) 0·46 0·35, 0·59 0·38 0·30, 0·49
Seafood 0·82 0·53, 1·27 0·57 0·39, 0·82
Functional Food 0·30 0·12, 0·79 0·22 0·11, 0·44
Nutraceutical 0·39 0·32, 0·47 0·46 0·28, 0·76
Combined 0·44 0·29, 0·65 0·37 0·25, 0·55
* Mean value was significantly different from that of the dietary record measure-
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Fig. 2. Percentage of EPA þ DHA in total fatty acids in the whole blood of (a) men and (b) women in each dietary advice group ( , Seafood; , Functional
Food; , Nutraceutical; , Combined). Values are means (n 45), with standard deviations represented by vertical bars. * Mean value was significantly different
from that of the corresponding baseline measurement (P,0·05; Bonferroni’s post hoc test following a significant F-value by the linear mixed model procedure).
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EPA þ DPAn-3 þ DHA and the percentage of n-3 HUFA in the
total HUFA biomarker in erythrocytes increased in weeks 4–52
relative to the baseline measurement.
Discussion
The present investigation uses a combination of multiple
assessment tools to characterise EPA þ DHA intake and
blood status over a 52-week period. By considering the
changes in the percentage of DHA in erythrocytes in contrast
to all the other measurements of the percentage of DHA
and/or the percentage of EPA in blood fractions assayed, as
well as diet assessments, it appears that adherence in the
present study was inconsistent through weeks 24 and 52.
A pattern of poor adherence after the week 12 visit, followed
by ‘compensatory’ EPA þ DHA intake shortly before the
visits in weeks 24 and 52, would potentially result in a low
percentage of DHA in erythrocytes and values above baseline
for all the other EPA and DHA blood measurements. A hypo-
thesised pattern of actual dietary EPA þ DHA intake over the
52-week period is depicted in Fig. 3.
DHA in erythrocytes appears to be a more accurate reflec-
tion of adherence to the n-3 HUFA intervention, as it takes
much longer to incorporate when compared with EPA in
general and DHA in plasma phospholipids(45). In erythrocytes,
DHA preferentially incorporates into phosphatidylethano-
lamine of the inner leaflet of lipid membrane bilayers, while
EPA incorporates into phosphatidylcholine of the outer
leaflet(46). Fatty acid remodelling of inner cell membranes is
relatively slow(22), therefore EPA can increase and decrease
rapidly in erythrocytes, while DHA turnover is slower(17).
DHA and DPAn-3 appear to compete for incorporation into
phospholipids(47,48) and DPAn-3 may have replaced DHA in
erythrocyte membranes in weeks 24 and 52, supporting our
hypothesis that EPA þ DHA intake was low for most of this
period. In contrast, plasma EPA, DPAn-3 and DHA respond
relatively quickly to dietary intake changes(17) as plasma
phospholipids are predominantly phosphatidylcholine of the
outer monolayer of lipoproteins. Plasma also contains cho-
lesteryl esters and TAG that can incorporate fatty acids(49),
but n-3 HUFA accumulation in these lipids is typically
low(18,45). Biomarkers of n-3 HUFA, such as the percentage
of EPA þ DHA, the percentage of EPA þ DPAn-3 þ DHA
and the percentage of n-3 HUFA in total HUFA, appear to be
most appropriate for characterising short-term changes in EPA
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Fig. 3. Percentage of (a) DHA, (b) n-3 docosapentaenoic acid (DPAn-3) and (c) EPA in erythrocyte ( ), plasma ( ) and whole-blood ( ) total fatty acids and
(d) measured (3 d diet record ( ) and hypothesised EPA þ DHA intake ( )). Values are means (n 45), with standard deviations represented by vertical bars
(3 d diet records are back-transformed loge means and standard deviations). * Mean value was significantly different from that of the corresponding baseline
measurement (P,0·05; Bonferroni’s post hoc test following a significant F-value by the linear mixed model procedure).
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intakes for individuals in observational studies. However,
the present findings suggest that DHA in erythrocytes
reflects adherence to n-3 HUFA intake over longer periods.
Determining the fatty acid composition of specific lipid classes
or erythrocytes such as phosphatidylethanolamine or phos-
phatidylserine could prove to be even more sensitive blood
biomarkers for adherence to the n-3 HUFA intervention, but
would greatly increase the analytical burden. Plasma and
whole blood levels may still be informative in observational
studies intended to examine ‘usual’ behaviour, but may be
problematic when used to assess dietary change.
The findings of non-adherence to the advice to increase
EPA and DHA intakes have an impact on the interpretation
of intervention studies. While recent meta-analyses(12,13)
have documented dose levels for intervention studies, the
issue of adherence to intake is not addressed. This is in part
because most n-3 HUFA intervention studies have reported
high adherence, but often this is determined by self-report
and dietary intake assessments(11,50), although some studies
have started to report plasma blood levels(9,10,51). The present
results suggest that reliance on dietary intake assessments
and plasma blood levels of n-3 HUFA in intervention studies
could result in an overestimation of adherence.
Adherence to dietary advice up to, but not beyond, the
initial 12 weeks of the study may be related to follow-up
frequency and/or participant fatigue. Study visits occurred
monthly from baseline to week 12, and subsequently follow-
ing 3- and 6-month intervals at weeks 24 and 52, respectively.
Adherence up to 12 weeks, but not 52 weeks, has been
observed previously following dietary advice to consume
fatty fish(14). In this previous fish advice study, dietary counsel-
ling was provided at the same time points as the present
study, plus an additional visit at week 36. The findings from
the present study suggest that dietary advice for free-living
individuals to increase the intake of EPA and DHA from
traditional sources, such as seafood, and novel sources,
including nutraceuticals, can be effective, but regular follow-
up and motivation may be needed to maintain long-term
adherence. The possibility of non-adherence in intervention
trials examining fish oil supplementation needs to be
considered.
Sex and advice group differences were not observed in
the percentage of DHA in erythrocytes but were detected
in the percentage of EPA þ DHA, EPA þ DPAn-3 þ DHA
and n-3 HUFA in total HUFA in whole blood. In the long
term, functional food advice was not successful in raising
the percentage of EPA þ DHA in whole blood, in both men
and women. This is probably due to the low amount of
EPA þ DHA per serving of functional food products that are
due to regulations(52) and/or potential changes in sensory
properties of the functional foods(53). As a result, several
functional foods must be consumed to achieve EPA þ DHA
intakes of 1 g/d. In contrast, the percentage of EPA þ DHA
in whole blood increased the most for men following the
seafood advice and for women following the nutraceutical
and combined advice.
Dietary assessments performed by both sexes can be
subject to response bias as women are influenced by social
desirability, a tendency to avoid criticism, and men are influ-
enced by social approval, a tendency to seek praise(54). Know-
ing that blood samples would be measured for n-3 HUFA
status at each study visit could have lead to compensatory
adherence immediately before study visits. EPA þ DHA
compensatory intakes before study visits could be accom-
plished with intake of oily fish or a few fish oil capsules.
Men may have been capable of achieving higher intakes of
EPA þ DHA after seafood advice or engaging in compensatory
EPA þ DHA consumption with seafood when compared with
women. As men typically consume larger portions of meat
when compared with women, it is plausible that their intake
of EPA þ DHA from seafood substitution could be greater(55),
and compensatory EPA þ DHA intake would be higher. Fish
oil nutraceutical users tend to be female(56), and it is possible
that women had higher compensatory EPA þ DHA intakes
from nutraceuticals when compared with men.
The n-3 HUFA intakes and adherence to dietary advice over
time attained herein may be different from what is achievable
by different populations. For ethical reasons, the study was
advertised as an n-3 fatty acid intervention and may have
attracted individuals with an interest in consuming n-3 fatty
acids. Clinical populations with existing health conditions
may be more motivated to adhere to dietary advice and
comply with fish oil supplementation. Study conclusions
herein were the same following the intention-to-treat and
completer analysis; however, loss to follow-up in the Seafood
and Functional Food advice groups may indicate difficulty
adhering to dietary strategies involving food substitution
instead of nutraceutical addition. Estimated intakes of EPA
by the Seafood advice group in weeks 4–52 may be an over-
estimation if the discrepancy between the diet record and
duplicate food measurements is due to the food compo-
sition database rather than to participant recording/food
collection error.
In conclusion, dietary advice to consume EPA þ DHA from
seafood or nutraceutical sources alone, or in combination with
functional foods, can increase EPA þ DHA intakes and levels
in blood in the short term. There may, however, be sex differ-
ences in the effectiveness of types of dietary advice. Dietary
intake assessments and other blood measurements of EPA or
DHA suggest long-term adherence to dietary advice, but
levels of DHA in erythrocytes indicate non-adherence. Rapid
incorporation of EPA into plasma and erythrocyte lipids, and
DHA into plasma lipids makes measures of EPA þ DHA sus-
ceptible to acute compensatory EPA þ DHA intake just
before clinical blood sampling visits during long-term inter-
vention studies. The percentage of DHA in erythrocytes
appears to capture long-term adherence to n-3 HUFA intakes
and could be an appropriate and much-needed marker of
adherence in long-term n-3 intervention trials. Disease end-
points could also be evaluated based on the percentage of
DHA in erythrocytes in studies where adherence to supplemen-
tation protocols cannot be assumed. Sex differences in blood
n-3 HUFA biomarker responses to different types of advice
indicate that tailoring dietary advice about EPA and DHA
to traits of individuals could increase adherence. Strategies to
improve adherence to dietary advice beyond 12 weeks are
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needed and the effect of increased follow-up frequency over
the long-term warrants investigation in the future.
Supplementary material
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